大都会人寿

最新新闻

• Glaukos Announces Topline Results From Its Phase 4 Trial Evaluating IDose TR With Cataract Surgery In Patients With Open-Angle Glaucoma Or Ocular Hypertension; Study Met Primary Efficacy Endpoint, Demonstrating Statistically Significant Superiority...
  Benzinga · 2026/10/9
• 评级变动
  UBS Maintains MetLife(MET.US) With Buy Rating, Raises Target Price to $110
  \u5e02\u573a\u8d44\u8baf · 2026/10/6
• Mizuho Securities Maintains MetLife(MET.US) With Buy Rating, Cuts Target Price to $109
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 评级变动
  Morgan Stanley Maintains MetLife(MET.US) With Buy Rating, Maintains Target Price $111
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 公司公告
  Laimu Co., Ltd.: Announcement by Laimu Co., Ltd. on the Completion of Cancellation of Stock Options for the Third Exercise Period of the 2023 Stock Option Incentive Plan, as the Exercise Conditions Were Not Met
  SZSI · 2026/5/14
• RBC Capital Maintains Warrior Met Coal(HCC.US) With Hold Rating, Maintains Target Price $110
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• 公司公告
  JUNSHI BIO: Overseas Regulatory Announcement – Junshi Biosciences Co., Ltd. Voluntarily Discloses that the Phase III Clinical Trial of Toripalimab in Combination with Chemotherapy for Perioperative Treatment of Patients with Resectable Stage II–III Non-Small Cell Lung Cancer Has Met Its Primary Endpoint at Final Analysis
  HKEX · 2026/5/26
• 评级变动
  UBS Maintains MetLife(MET.US) With Buy Rating, Maintains Target Price $105
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 公司公告
  Baili Tianheng: Sichuan Baili Tianheng Pharmaceutical Co., Ltd. voluntarily discloses an announcement regarding the interim analysis of its Phase III clinical trial of Yizekang® (LunKang Yilong Tuodan Kang, BL‑B01D1/iza‑bren) for the treatment of locally advanced, recurrent, or metastatic HR+HER2‑negative breast cancer, which has met the primary endpoint.
  SZSI · 2026/8/26
• 评级变动
  TD Cowen Maintains MetLife(MET.US) With Buy Rating, Raises Target Price to $110
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 评级变动
  Barclays Maintains MetLife(MET.US) With Buy Rating, Raises Target Price to $111
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• KBW Maintains MetLife(MET.US) With Buy Rating, Maintains Target Price $108
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• 公司公告
  Guangting Information: Verification Opinion of the Board\'s Remuneration and Assessment Committee on Whether the Vesting Conditions for the First Vesting Period of the Initial Grant under the 2025 Restricted Stock Incentive Plan Have Been Met.
  SZSI · 2026/6/9
• 评级变动
  Raymond James Maintains MetLife(MET.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• Liao Min, Vice Minister of Finance, met with David Solomon, President and Chief Executive Officer of Goldman Sachs.
  Latest · 2026/10/10
• 评级变动
  Piper Sandler Maintains MetLife(MET.US) With Buy Rating, Maintains Target Price $110
  \u5e02\u573a\u8d44\u8baf · 2026/9/25
• 评级变动
  Kelun-Biotech (06990.HK): H1 2026 product sales met expectations; domestic volume growth of sac-TMT and overseas development continue to advance.
  Tianfeng Securities · 2026/9/29
• 评级变动
  UBS Maintains Warrior Met Coal(HCC.US) With Buy Rating, Raises Target Price to $102
  \u5e02\u573a\u8d44\u8baf · 2026/10/8
• 公司公告
  4: Warrior Met Coal | 4: Statement of changes in beneficial ownership of securities-Officer Gant Kelli K.
  SEC · 2026/6/5
• 评级变动
  Jefferies Maintains MetLife(MET.US) With Buy Rating, Raises Target Price to $115
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  Inovance Technology (300124): 1H2026 performance met expectations; general automation business achieved steady growth.
  Huaxing Securities · 2026/9/9
• 评级变动
  Piper Sandler Upgrades MetLife(MET.US) to Buy Rating, Raises Target Price to $110
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• Wang Jun, Deputy Commissioner of the General Administration of Customs, met with Habib Tucci, Secretary General of the International Road Transport Union (IRU), at the Administration.
  Latest · 2026/9/29
• 评级变动
  Kuaishou-W (01024.HK) Q2 2026 Earnings Review: Second-quarter results met expectations; short-term headwinds persist, but the valuation is already attractive.
  Soochow Securities · 2026/8/31
• 评级变动
  BYD (002594) 2026 Interim Report Commentary: Q2 results met expectations, and the trend of year-on-year and quarter-on-quarter improvement in per-vehicle profitability has been established.
  Huachuang Securities · 2026/9/1

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。